Roivant Sciences Ltd. - 02 Oct 2023 Form 4 Insider Report for Immunovant, Inc. (IMVT)

Role: Director, 10%+ Owner
Signature: /s/ Matt Maisak, as Authorized Signatory
Issuer symbol: IMVT
Transactions as of: 02 Oct 2023
Net transactions value: +$228,000,000
Form type: 4
Filing time: 04 Oct 2023, 17:15:20 UTC
Previous filing: 07 Oct 2022
Next filing: 15 Jan 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IMVT	Common Stock, $0.0001 par value per share	Award	$169,999,992	+4,473,684	+6.1%	$38.00	78,279,015	02 Oct 2023	Direct
transaction	IMVT	Common Stock, $0.0001 par value per share	Purchase	$58,000,008	+1,526,316	+1.9%	$38.00	79,805,331	02 Oct 2023	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Remarks:

The Reporting Person is deemed to be a "director by deputization" of the Issuer for purposes of Section 16 of the Securities Exchange Act of 1934 by virtue of the fact that Frank M. Torti, M.D. (who serves as Vant Chair of Roivant Sciences, Inc. ("RSI"), a subsidiary of the Reporting Person), Eric Venker, M.D., Pharm.D. (who serves as President, Chief Operating Officer of RSI) and Andrew Fromkin (who serves as the Vant Portfolio Operating Partner for RSI) each currently serve on the board of directors of the Issuer on behalf of the Reporting Person.